Frontiers in pharmacology · 2025
Efficacy and influencing factors analysis of SGLT2 inhibitors in treating heart failure following acute myocardial infarction.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Du Haiping, Xu Hui, Bao Jinwei
Аннотация
PURPOSE: Heart failure (HF) following acute myocardial infarction (AMI) significantly impacts morbidity and mortality. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus, have shown cardiovascular benefits. This study evaluates the efficacy of SGLT2 inhibitors in treating HF post-AMI compared to conventional treatments.
METHODS: We conducted a retrospective cohort study at our hospital from September 2022 to September 2024 involving 315 patients with HF post-AMI. Patients were categorized into a conventional treatment group (n = 140) and an SGLT2 inhibitor group (n = 175), with the latter further divided into effective (n = 154) and ineffective (n = 21) subgroups. Cardiac function was assessed pre- and post-treatment using echocardiography and serum biomarkers. Baseline characteristics and potential predictors of SGLT2 efficacy were also analyzed.
RESULTS: The SGLT2 group exhibited significant improvements in left ventricular ejection fraction (LVEF), decreased NT-proBNP, troponin I, and hs-CRP levels compared to the conventional group (P < 0.001). The overall effectiveness rate was 88.00% versus 75.71% in the conventional group (P = 0.004). Lower baseline LVEF and higher NT-proBNP levels were significant predictors of better outcomes. Notably, adverse reactions such as angina were reduced in the SGLT2 group.
CONCLUSION: SGLT2 inhibitors were associated with enhanced cardiac function and reduce cardiac stress markers in HF patients post-AMI, suggesting their potential as an adjunctive therapy. Lower baseline LVEF and higher NT-proBNP levels may predict better response, suggesting their utility in personalized treatment strategies. This was a retrospective single-center study, and further prospective trials are needed to confirm these findings.
METHODS: We conducted a retrospective cohort study at our hospital from September 2022 to September 2024 involving 315 patients with HF post-AMI. Patients were categorized into a conventional treatment group (n = 140) and an SGLT2 inhibitor group (n = 175), with the latter further divided into effective (n = 154) and ineffective (n = 21) subgroups. Cardiac function was assessed pre- and post-treatment using echocardiography and serum biomarkers. Baseline characteristics and potential predictors of SGLT2 efficacy were also analyzed.
RESULTS: The SGLT2 group exhibited significant improvements in left ventricular ejection fraction (LVEF), decreased NT-proBNP, troponin I, and hs-CRP levels compared to the conventional group (P < 0.001). The overall effectiveness rate was 88.00% versus 75.71% in the conventional group (P = 0.004). Lower baseline LVEF and higher NT-proBNP levels were significant predictors of better outcomes. Notably, adverse reactions such as angina were reduced in the SGLT2 group.
CONCLUSION: SGLT2 inhibitors were associated with enhanced cardiac function and reduce cardiac stress markers in HF patients post-AMI, suggesting their potential as an adjunctive therapy. Lower baseline LVEF and higher NT-proBNP levels may predict better response, suggesting their utility in personalized treatment strategies. This was a retrospective single-center study, and further prospective trials are needed to confirm these findings.